Immunotherapy combo shows promise for rare skin cancer
NCT ID NCT03071406
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 27 times
Summary
This study tests whether adding a precise type of radiation (SBRT) to a two-drug immunotherapy combination (nivolumab and ipilimumab) works better than the drugs alone for people with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. About 50 adults whose cancer has spread or cannot be removed are participating. The goal is to see if the combination shrinks tumors and delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.